Olivera Finn

Olivera Finn

Department Of Medicine, Division Of Oncology, Stanford University Medical Center, 94305, Stanford, California

Direct Impact

Concepts for which Olivera Finn has direct influence:

esophageal cancer
muc1 vaccine
poly iclc
advanced prostate
acid stabilized
tissue esophagus
lymph node

External impact

Concepts related to the work of other authors for which Olivera Finn has influence:

t-cell differentiation antigen
chronic lymphocytic leukemia cells
bone marrow
50000 daltons
molecular weights
igg2a antibody
immune precipitates

Prominent publications by Olivera Finn

KOL-Index: 11 In the present paper, we will summarize studies we have performed on two distinct human lymphocyte cell surface antigens defined by monoclonal antibodies: Leu-1 and HLA-DR.
Known for
Leu-1 | -Dr | Antibodies Surface
KOL-Index: 2 The purpose of this study is to identify markers in the blood and tissue that could indicate risk factors for the development and progression of esophagus cancer. This research aims to collect medical history, blood, and tissue samples from patients who present with an esophageal disorder. Identifying genetic and behavioral risk factors involved in the development of esophageal cancer might ...
Known for
Small Piece | Genetic Hereditary | Esophageal Disorder
KOL-Index: 2 All subjects will receive the vaccine subcutaneously every 3 weeks x 3 with optional yearly booster vaccines up to and including 5 years post last vaccine for those patients who are confirmed responders to the vaccine . The rationale for using Poly-ICLC as an adjuvant are two ongoing trials at University of Pittsburgh Cancer Institute (UPCI) of the MUC1 100mer peptide vaccine - one as a ...
Known for
Nsclc Trial | Therapeutic Vaccine
KOL-Index: 2 The purpose of this study is to determine the effectiveness of a drug called Poly-ICLC, also known as HiltonolTM, in boosting the body's immune system's response to an experimental vaccine therapy (called the MUC-1 vaccine). Detailed Description This is a one-arm clinical trial, to evaluate 2 doses of poly-ICLC for reversing systemic immuno-suppression: 25 μg/kg and 50 μg/kg. These doses ...
Known for
Systemic Immunosuppression | Dendritic Number | Clinically Stable | Immunologic Response

Department of Medicine, Division of Oncology, Stanford University Medical Center, 94305, Stanford, California

https://www.g2.com/products/key-opinion-leaders-kols/reviews https://www.bbb.org/us/fl/doral/profile/data-analytics/key-opinion-leaders-0633-92023858 https://www.trustpilot.com/review/keyopinionleaders.com https://www.yelp.com/biz/key-opinion-leaders-miami


© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172